HOME >> BIOLOGY >> NEWS
Moderate exercise may delay congestive heart failure, CU-Boulder study suggests

A new University of Colorado at Boulder study involving laboratory rats that indicates low-intensity exercise may significantly delay the onset of congestive heart failure appears to have some promising implications for humans.

According to Professor Russell Moore of CU-Boulder's integrative physiology department who led the study, lab rats carrying the genetic characteristics for spontaneously developing heart failure were shown to live significantly longer if they exercised moderately on a treadmill. The exercise protocol, the equivalent of daily, leisurely strolls in humans, extended the life expectancy of the rat study group by at least 10 percent to 15 percent, according to the study.

"Assuming the results are applicable to humans, low-intensity exercise is likely to have benefits to humans in early stages of congestive heart failure," he said.

The study was published in the November 2005 issue of the American Journal of Physiology -- Heart and Circulatory Physiology. The study was co-authored by CU-Boulder doctoral student Craig Emter, Associate Professor Sylvia McCune, Research Associate Genevieve Sparagna and Ohio State University Professor Judith Radin.

"Our study, coupled with several human studies conducted elsewhere, shows a definite trend indicating that moderate intensity exercise has a potential role in stemming the downward spiral in heart failure," he said.

Moore said a unique feature of the CU-Boulder study was that the delay in the onset of CHF in the rats through moderate exercise was accomplished without reducing hypertension, or high blood pressure, in the animals. Most people in the early stages of development of heart failure also have hypertension, which is regularly treated to help improve the prognosis of CHF sufferers, said Moore.

Although several human studies in the last 10 to 20 years have shown that moderate exercise does not appear to harm CHF sufferers, the positive benefits
'"/>


8-Dec-2005


Page: 1 2 3

Related biology news :

1. Moderate drinking may help older women live longer
2. Moderate drinking may boost memory, study suggests
3. Moderate lifetime reductions in LDL cholesterol dramatically reduce risk of heart disease
4. Moderate alcohol consumption enhances the formation of new nerve cells
5. Moderate aerobic exercise improves cardiovascular and nervous system function in HIV+
6. Cardio exercise benefits in male vs. female hearts
7. Caffeine and exercise can team up to prevent skin cancer
8. Adult survivors of childhood leukemia exercise less, worsening high risk for obesity and illness
9. New clue into how diet and exercise enhance longevity
10. Exercise, exercise, rest, repeat -- how a break can help your workout
11. Losing weight after pregnancy -- diet and exercise better than diet alone

Post Your Comments:
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
(Date:7/29/2015)... 2015 Research and ... of the "Global Biosimilars Market, 2015 - ... The Global Biosimilars Market, 2015 - 2025, report ... biosimilars market. With the blockbuster biologics losing patent ... biosimilars are being viewed as viable substitutes to ...
(Date:7/29/2015)... July 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... will be released on Thursday, August 13, 2015, before ... Pfenex management will host a conference call to discuss ... press release outlining the financial results and business update ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and ...
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
Cached News: